Key stats
About BMO MSCI GENOMIC INN INDEX ETF CAD UNIT
Expense ratio
0.47%
Home page
Inception date
Jan 14, 2021
The fund portfolio is comprised of companies whose business activities include gene editing, agricultural biotechnology, molecular diagnostics, genome related hardware for analytics and diagnostics, bioinformatics, targeted therapeutics, and gene and stem cell therapies. A stock relevance score is calculated by taking into account the portion of a companys revenue which is derived from the selected business segments, and those with a relevance score of 25% or more are eligible for inclusion in the index. Moreover, stocks are weighted by the product of their relevance score and their float-adjusted market-cap (subject to 5% capping). The fund is rebalanced semi-annually.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.24%
Health Technology85.36%
Commercial Services8.52%
Health Services4.92%
Electronic Technology0.28%
Finance0.05%
Consumer Non-Durables0.05%
Technology Services0.04%
Bonds, Cash & Other0.76%
Cash0.76%
Stock breakdown by region
North America84.51%
Europe10.74%
Asia4.66%
Oceania0.08%
Latin America0.00%
Africa0.00%
Middle East0.00%
Top 10 holdings
Dividends
Dividend payout history